Nonimmunogenic Staphylokinase Noninferior to Alteplase in Ischemic Stroke
Researchers assessed the safety and efficacy of nonimmunogenic recombinant staphylokinase compared with alteplase in patients with acute ischemic stroke within 4.5 hours following symptom onset.
